Minor structural modifications convert a selective PPARα agonist into a potent, highly selective PPARδ agonist

We report the solid-phase synthesis and pharmacological evaluation of a new series of small-molecule agonists of the human peroxisome proliferator-activated receptor δ (PPARδ) based on a lead structure from our PPARα program. Compound 33 showed good pharmacokinetics.

We report the solid-phase synthesis and pharmacological evaluation of a new series of small-molecule agonists of the human peroxisome proliferator-activated receptor δ (PPARδ) based on a lead structure from our PPARα program. Compound 33 showed good pharmacokinetics.Figure optionsDownload as PowerPoint slide